Everolimus (EVE) plus exemestane (EXE) vs EVE alone or capecitabine (CAP) for estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): BOLERO-6, an open-label phase 2 study
Jerusalem G. H. M., Kovalenko E., Yardley D. A., De Boer R. H., Hurvitz S. A., Ejlertsen B., ...Daha Fazla
JOURNAL OF CLINICAL ONCOLOGY, cilt.36, sa.15, 2018 (SCI-Expanded, Scopus)